Clinical Trials
48 trialsSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
SUNRAY-01
Eli Lilly and Company
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
LUNAR-4
NovoCure Ltd.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeOne Medicines
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
CANOPY-1
Novartis
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
EBNK-ST-001
Essen Biotech
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics, Inc.
PRIMING
Royal Marsden NHS Foundation Trust
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
LUNAR-2
NovoCure Ltd.
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
IRRADIATE-Lung
NYU Langone Health
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
SWIPE
Bank of Cyprus Oncology Centre
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
University of California, San Francisco
MK-3475-E90
Wellmarker Bio
PIL
Augusta University
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation